Bli medlem
Bli medlem

Du är här


Biocartis Group NV: Biocartis announces publication of 2015 annual report and invitation to annual general meeting

Mechelen, Belgium, 12 April 2016
- Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular
diagnostics company, today announces the publication of its 2015 annual
report and the invitation for its annual general shareholders' meeting

The 2015 annual report provides an overview of the figures and performance of
Biocartis for the financial year ended 31 December 2015 and can now be
downloaded from the website of the Company ( as a
PDF file.

Biocartis will hold its AGM on 13 May 2016 at 14:00 p.m. CEST (Central
European Summer Time) and is delighted to invite its shareholders and warrant
holders. A copy of the convening notice for the AGM, including a description
of the formalities to participate in the AGM, is available on the website of
the Company ( The most important resolutions
included in the agenda of the AGM relate to the annual accounts for the
financial year ended on 31 December 2015 and the composition of the Board of
Directors of the Company, including the appointment of Hilde Eylenbosch as a
new independent director.

----- END ----

For more information:


Renate Degrave, Corporate Communications&Investor Relations
+32 15 632 600 |

About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at
improving clinical practice for the benefit of patients, clinicians, payers
and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system
that offers accurate, highly reliable molecular information from virtually
any biological sample in virtually any setting. Idylla(TM) addresses the
growing demand for personalized medicine by allowing fast and effective
treatment selection and treatment progress monitoring. Biocartis launched the
Idylla(TM) platform in September 2014. Biocartis is developing and marketing
a rapidly expanding test menu addressing key unmet clinical needs in oncology
and infectious diseases. These areas represent respectively the fastest
growing and largest segments of the MDx market worldwide. Today, Biocartis
has four oncology tests and one infectious disease test on the market. More


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biocartis Group NV via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.